FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912484087> ?p ?o ?g. }

• W2912484087 endingPage "190" @default.
• W2912484087 startingPage "190" @default.
• W2912484087 abstract "190 Background: Data from the KEYNOTE-028 study (NCT02054806) suggested that pembrolizumab (pembro) has clinical activity in a subset of patients (pts) with heavily pretreated neuroendocrine tumors (NET). The KEYNOTE-158 study (NCT02628067) is a phase II basket study investigating the antitumor activity of pembro in 10 specific cancer types. An analysis of the 107 pts included in the NET cohort is presented. Methods: Key eligibility criteria for this cohort included well- and moderately-differentiated NET of the lung, appendix, small intestine, colon, rectum, or pancreas; progression on or intolerance to ≥ 1 line of standard therapy; ECOG PS 0 or 1; and provision of a tumor sample for biomarker analysis. Pts received pembrolizumab 200 mg Q3W for 2 y or until progression, intolerable toxicity, or physician or patient decision. Tumor imaging was performed every 9 wks for the first 12 mo, and every 12 wks thereafter. PD-L1 positivity, defined as a combined positive score (CPS) ≥ 1, was evaluated retrospectively by IHC. Primary endpoint was ORR assessed per RECIST v1.1 by independent central radiology review. Secondary endpoints included DOR, PFS, OS, and safety. Results: 107 pts were treated. Median age was 59 (range, 29-80) y, 44.9% had ECOG PS 1, and 67.3% received ≥ 2 prior therapies for advanced disease. 15.9% of enrolled pts had PD-L1+ tumors. As of the January 15, 2018 data cutoff, the median follow-up duration was 18.6 (range, 0.2-22.7) mo. ORR was 3.7% (95% CI, 1.0-9.3), with 0 CR and 4 PR (3 pancreatic and 1 gastrointestinal [unknown primary]). 61 pts had SD as best response. The 4 responses were observed in pts with PD-L1 negative tumors. Median DOR had not been reached (range, 4.1-15.9+), with 3 of 4 responses ongoing after ≥ 9 mo follow-up. Median (95% CI) PFS was 4.1 (3.5-5.4) mo, and the 6-mo PFS rate was 38.2%. Median OS (95% CI) had not been reached (18.8-not reached), and the 6-mo OS rate was 84.6%. Treatment-related AEs occurred in 75.7% of pts, and the most common was fatigue (21.5%). 20.6% of pts had treatment-related grade 3-4 AEs. Conclusions: Pembrolizumab monotherapy showed limited antitumor activity and manageable safety in pts with previously treated advanced NET. Clinical trial information: NCT02628067." @default.
• W2912484087 created "2019-02-21" @default.
• W2912484087 creator A5001115937 @default.
• W2912484087 creator A5010925062 @default.
• W2912484087 creator A5016994371 @default.
• W2912484087 creator A5018910129 @default.
• W2912484087 creator A5026538331 @default.
• W2912484087 creator A5028020706 @default.
• W2912484087 creator A5033960518 @default.
• W2912484087 creator A5035552610 @default.
• W2912484087 creator A5037357027 @default.
• W2912484087 creator A5038614419 @default.
• W2912484087 creator A5058238015 @default.
• W2912484087 creator A5061200817 @default.
• W2912484087 creator A5065290717 @default.
• W2912484087 creator A5065522570 @default.
• W2912484087 creator A5065581439 @default.
• W2912484087 creator A5068503288 @default.
• W2912484087 creator A5072400207 @default.
• W2912484087 creator A5078332643 @default.
• W2912484087 date "2019-02-01" @default.
• W2912484087 modified "2023-10-17" @default.
• W2912484087 title "Pembrolizumab treatment of advanced neuroendocrine tumors: Results from the phase II KEYNOTE-158 study." @default.
• W2912484087 doi "https://doi.org/10.1200/jco.2019.37.4_suppl.190" @default.
• W2912484087 hasPublicationYear "2019" @default.
• W2912484087 type Work @default.
• W2912484087 sameAs 2912484087 @default.
• W2912484087 citedByCount "17" @default.
• W2912484087 countsByYear W29124840872019 @default.
• W2912484087 countsByYear W29124840872020 @default.
• W2912484087 countsByYear W29124840872021 @default.
• W2912484087 crossrefType "journal-article" @default.
• W2912484087 hasAuthorship W2912484087A5001115937 @default.
• W2912484087 hasAuthorship W2912484087A5010925062 @default.
• W2912484087 hasAuthorship W2912484087A5016994371 @default.
• W2912484087 hasAuthorship W2912484087A5018910129 @default.
• W2912484087 hasAuthorship W2912484087A5026538331 @default.
• W2912484087 hasAuthorship W2912484087A5028020706 @default.
• W2912484087 hasAuthorship W2912484087A5033960518 @default.
• W2912484087 hasAuthorship W2912484087A5035552610 @default.
• W2912484087 hasAuthorship W2912484087A5037357027 @default.
• W2912484087 hasAuthorship W2912484087A5038614419 @default.
• W2912484087 hasAuthorship W2912484087A5058238015 @default.
• W2912484087 hasAuthorship W2912484087A5061200817 @default.
• W2912484087 hasAuthorship W2912484087A5065290717 @default.
• W2912484087 hasAuthorship W2912484087A5065522570 @default.
• W2912484087 hasAuthorship W2912484087A5065581439 @default.
• W2912484087 hasAuthorship W2912484087A5068503288 @default.
• W2912484087 hasAuthorship W2912484087A5072400207 @default.
• W2912484087 hasAuthorship W2912484087A5078332643 @default.
• W2912484087 hasConcept C121608353 @default.
• W2912484087 hasConcept C126322002 @default.
• W2912484087 hasConcept C141071460 @default.
• W2912484087 hasConcept C143998085 @default.
• W2912484087 hasConcept C203092338 @default.
• W2912484087 hasConcept C2777701055 @default.
• W2912484087 hasConcept C2779066768 @default.
• W2912484087 hasConcept C2780057760 @default.
• W2912484087 hasConcept C31760486 @default.
• W2912484087 hasConcept C535046627 @default.
• W2912484087 hasConcept C71924100 @default.
• W2912484087 hasConcept C72563966 @default.
• W2912484087 hasConcept C90924648 @default.
• W2912484087 hasConceptScore W2912484087C121608353 @default.
• W2912484087 hasConceptScore W2912484087C126322002 @default.
• W2912484087 hasConceptScore W2912484087C141071460 @default.
• W2912484087 hasConceptScore W2912484087C143998085 @default.
• W2912484087 hasConceptScore W2912484087C203092338 @default.
• W2912484087 hasConceptScore W2912484087C2777701055 @default.
• W2912484087 hasConceptScore W2912484087C2779066768 @default.
• W2912484087 hasConceptScore W2912484087C2780057760 @default.
• W2912484087 hasConceptScore W2912484087C31760486 @default.
• W2912484087 hasConceptScore W2912484087C535046627 @default.
• W2912484087 hasConceptScore W2912484087C71924100 @default.
• W2912484087 hasConceptScore W2912484087C72563966 @default.
• W2912484087 hasConceptScore W2912484087C90924648 @default.
• W2912484087 hasIssue "4_suppl" @default.
• W2912484087 hasLocation W29124840871 @default.
• W2912484087 hasOpenAccess W2912484087 @default.
• W2912484087 hasPrimaryLocation W29124840871 @default.
• W2912484087 hasRelatedWork W2406666623 @default.
• W2912484087 hasRelatedWork W2568357966 @default.
• W2912484087 hasRelatedWork W2886193299 @default.
• W2912484087 hasRelatedWork W2947556250 @default.
• W2912484087 hasRelatedWork W3047040967 @default.
• W2912484087 hasRelatedWork W3177224496 @default.
• W2912484087 hasRelatedWork W3182090251 @default.
• W2912484087 hasRelatedWork W3196177384 @default.
• W2912484087 hasRelatedWork W4225141849 @default.
• W2912484087 hasRelatedWork W4322775203 @default.
• W2912484087 hasVolume "37" @default.
• W2912484087 isParatext "false" @default.
• W2912484087 isRetracted "false" @default.
• W2912484087 magId "2912484087" @default.
• W2912484087 workType "article" @default.